Nuwellis, Inc. (NUWE)
NASDAQ: NUWE · Real-Time Price · USD
1.480
0.00 (0.00%)
Oct 2, 2024, 4:00 PM EDT - Market closed
Nuwellis Revenue
Nuwellis had revenue of $2.19M in the quarter ending June 30, 2024, with 5.73% growth. This brings the company's revenue in the last twelve months to $9.01M, up 8.54% year-over-year. In the year 2023, Nuwellis had annual revenue of $8.86M with 3.76% growth.
Revenue (ttm)
$9.01M
Revenue Growth
+8.54%
P/S Ratio
0.03
Revenue / Employee
$152,780
Employees
59
Market Cap
2.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.86M | 321.00K | 3.76% |
Dec 31, 2022 | 8.54M | 622.00K | 7.85% |
Dec 31, 2021 | 7.92M | 480.00K | 6.45% |
Dec 31, 2020 | 7.44M | 1.93M | 35.02% |
Dec 31, 2019 | 5.51M | 513.00K | 10.26% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Healthcare Triangle | 21.93M |
Tonix Pharmaceuticals Holding | 12.46M |
ReShape Lifesciences | 8.05M |
INVO Bioscience | 5.77M |
China SXT Pharmaceuticals | 1.93M |
NUWE News
- 7 days ago - Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 5 weeks ago - Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 7 weeks ago - Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Nuwellis, Inc. Announces Second Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE™ Therapy at Cincinnati Children's - GlobeNewsWire
- 2 months ago - Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024 - GlobeNewsWire
- 2 months ago - Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children's - GlobeNewsWire